Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v3.23.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Current assets:    
Cash $ 197,304 $ 68,615
Accounts receivable 12,653 35,378
Grant receivable 92,426 130,152
Prepaid expenses 127,310 82,765
Total current assets 429,693 316,910
Property and equipment, net 63,782 76,572
Right to use assets 209,147 270,406
Other assets:    
Patents, net 9,617 10,206
Software development costs 0 47,980
Deposits, long term 44,520 44,520
Total other assets 54,137 102,706
Total assets 756,759 766,594
Current liabilities:    
Accounts payable and accrued expenses, including related party payables of $1,342,869 and $1,077,088, respectively 4,296,550 3,907,954
Deferred revenue, short term 15,909 33,256
Lease liability, short term 142,160 134,343
Notes payable, net of debt discount of $11,751 and $23,878, respectively 359,729 297,602
Notes payable, related parties, net of debt discount of $0 and $49,473, respectively 888,383 990,637
Total current liabilities 5,702,731 5,363,792
Long term liabilities:    
Economic Injury Disaster loan, long term 73,164 73,850
Royalty obligation, net of discount of $5,142,902 and $5,376,790, related parties 3,579,198 3,345,310
Lease liability, long term 108,131 181,328
Deferred revenue, long term 4,045 4,045
Total liabilities 9,467,269 8,968,325
Deficit:    
Common stock, $0.001 par value; 750,000,000 shares authorized, 8,519,489 and 7,718,636 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively 8,520 7,719
Common stock subscribed 100,000 100,000
Additional paid in capital 67,554,849 66,130,296
Accumulated deficit (76,268,198) (74,336,105)
Total deficit attributable to BioCorRx Inc. (8,583,213) (8,076,474)
Non-controlling interest (127,297) (125,257)
Total deficit (8,710,510) (8,201,731)
Total liabilities and deficit 756,759 766,594
Series A Convertible Preferred Stock [Member]    
Preferred stock, no par value, 600,000 authorized    
Preferred stock value 16,000 16,000
Convertible Series B Preferred Stock [Member]    
Preferred stock, no par value, 600,000 authorized    
Preferred stock value $ 5,616 $ 5,616